Back to results
US 2013/0158035 A1Published application
Antimetastatic compounds
AssigneeBrigham Young University
InventorMarc Hansen
Life of this patent
Estimating the term…
Abstract
Screening methods for identifying compounds and compounds and pharmaceutical compositions for treating and preventing cancer are disclosed. The compounds affect signal transduction downstream of the MET receptor.
Claims29
A pharmaceutical composition comprising a compound of formula I-I
- wherein W1 is selected from O, OCH2, OCH3, OCH2CH3, CH2, and CH3;
- W2 is selected from O, OCH2, OCH3, OCH2CH3, CH2, and CH3;
- W3 is selected from H and OCH3;
- Z if present is alkylene;
- each R if present is independently selected from halogen, hydroxyl, alkoxy, benzylalkoxy, alkyl, CF3, OCF3, nitro, fused aryl, fused heterocycle, S-alkyl, NH2, NH-alkyl, and N(alkyl)2;
- n is an integer of from 0 to 3;
- and
- pharmaceutically acceptable salts thereof;
- and
- a pharmaceutically acceptable carrier.
7 more elements
7-11. (canceled)
15-16. (canceled)
18-19. (canceled)
(canceled)
(canceled)
25-37. (canceled)
39-40. (canceled)
A pharmaceutical composition comprising a compound of formula A-I
- wherein W is selected from O, S, and —C(R4)═C(R5)—;
- R1 is selected from alkyl, —C(O)NH2—, and H
- R2 is selected from alkyl, halogen, morpholino, and H;
- R3 is selected from CO2H, halogen, and H;
- R4, if present, is selected from halogen, hydroxyl, nitro, H, or together with R5 form a fused phenyl ring;
- R5, if present, is selected from halogen, alkoxy, H, or together with one of R4 and R6 form a fused phenyl ring;
- R6 is selected from alkyl, alkoxy, OCH2C≡CH, halogen, and H;
- R7 is selected from alkoxy, halogen, and H;
- Z is selected from —N═C— and —NH—CH2—;
- pharmaceutically acceptable salts thereof;
- and
- a pharmaceutically acceptable carrier.
9 more elements
44-66. (canceled)
A pharmaceutical composition comprising a compound of formula B-I
- wherein A is selected from —C(O)NH—, —NHC(O)—, —NHC(O)CH2—O—, —NHS(O)2—, —S(O)2NH—, —OCH2C(O)NH—, and —O(O)—;
- W is selected from N, C—H, C—R1, C—R2, and C—R3;
- each of R1, R2, and R3 if present is independently selected from halo, alkyl, alkoxy, optionally substituted aryl, hydroxyl;
- each of R4 and R5 if present is selected from halo, alkyl, alkoxy, C(O)alkyl, C(O)NH2, NH(CO)alkyl, NHalkyl, N(alkyl)2, NH(aryl), nitro, C(O)aryl, C(O)-optionally substituted heterocycle, optionally substituted heterocycle;
- and
- pharmaceutically acceptable salts thereof;
- and
- a pharmaceutically acceptable carrier.
5 more elements
68-134. (canceled)
A pharmaceutical composition comprising a compound of formula C-I
- wherein R1 is selected from alkyl;
- R2 is selected from aryl optionally substituted with one alkoxy and heteroaryl;
- R3 is selected from alkyl, cycloalkyl, alkylcycloalkyl optionally substituted with alkyl, alkylheterocyclyl, and alkylaryl optionally substituted with alkyl;
- pharmaceutically acceptable salts thereof;
- and
- a pharmaceutically acceptable carrier.
3 more elements
136-156. (canceled)
Dependencies are inferred from the claim text.